FDA Approves First Subcutaneous Infliximab for Crohn's and ulcerative colitis Maintenance Therapy.

Published Date: 26 Oct 2023

It was announced on October 22, 2023, that infliximab-dyyb would be approved as a maintenance therapy for patients with Crohn's disease and moderately to severely active ulcerative colitis after IV infliximab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

3.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.

4.

AI System Beats Radiologists in Detecting Clinically Significant Prostate Cancer

5.

In heavily pretreated DLBCL, Triplet Scores a Survival Victory.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot